Huakang Biomedical Holdings Company Limited reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was CNY 6.95 million compared to CNY 6.4 million a year ago. Net income was CNY 0.386 million compared to net loss of CNY 0.295 million a year ago. Basic earnings per share from continuing operations was CNY 0.0009 compared to basic loss per share from continuing operations of CNY 0.0007 a year ago.
For the nine months, sales was CNY 18.75 million compared to CNY 18.57 million a year ago. Net loss was CNY 0.555 million compared to CNY 2.34 million a year ago. Basic loss per share from continuing operations was CNY 0.0013 compared to CNY 0.0058 a year ago.